Citrini Bullish on Life Science Stocks After Testing Claude Science

On October 21, according to Bloomberg Technology, Citrini Research noted after testing Anthropic PBC's Claude Science that life science companies are expected to benefit from the AI-driven drug discovery boom. The independent investment research firm identified Charles River Laboratories International Inc. and Revvity Inc. as preferred life science targets that could benefit from advancements in AI within drug discovery. Citrini's assessment stemmed from its use of the Anthropic tool to create a new drug candidate, a process demonstrating that AI can shorten research time and stimulate demand for experimental validation.